| Literature DB >> 35645613 |
Elnaz Salim1, Vasudevan Ramachandran2, Neda Ansari1, Patimah Ismail1, Mohd Hazmi Mohamed3, Nur Afiqah Mohamad4,5, Liyana Najwa Inche Mat6.
Abstract
Objectives: Endothelin-1 (ET-1), the most potent endogenous vasoconstrictor, generated by enzymatic cleavage catalyzed by an endothelin-converting enzyme (ECE), plays a significant role in the regulation of hypertension.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35645613 PMCID: PMC9126669 DOI: 10.1155/2022/9129960
Source DB: PubMed Journal: Genet Res (Camb) ISSN: 0016-6723 Impact factor: 1.375
Clinical and biochemical parameter of EH patients and control subjects.
| Parameter | Control (%) | Case (%) |
|
|---|---|---|---|
| No. of samples | 196 | 177 | |
| Age | 37.17 ± 9.408 | 57.02 ± 9.516 | <0.001 |
| Gender | |||
| Male | 98 (50.0%) | 106 (59.9%) | 0.056 |
| Female | 98 (50.6%) | 71 (40.0%) | |
| BMI | 23.58 ± 3.82 | 28.77 ± 4.64 | <0.001 |
| WHR | 0.91 ± 0.14 | 0.899 ± 0.098 | <0.001 |
| FPG | 5.50 ± 1.38 | 6.55 ± 2.42 | <0.001 |
| HbA1c | 2.73 ± 2.93 | 6.47 ± 1.87 | <0.001 |
| SBP | 121.52 ± 10.24 | 156.80 ± 12.13 | <0.001 |
| DBP | 78.21 ± 7.43 | 94.49 ± 5.8 | <0.001 |
| Cholesterol | 4.83 ± 0.93 | 5.04 ± 1.10 | 0.049 |
| LDL | 2.63 ± 0.94 | 2.86 ± 0.88 | 0.20 |
| HDL | 1.10 ± 0.35 | 1.25 ± 0.74 | 0.015 |
| TG | 1.46 ± 0.65 | 1.85 ± 0.99 | <0.001 |
Note: BMI = body mass index; WHR = waist-to-hip ratio; FPG = fasting plasma glucose; HbA1c = hemoglobin A1c; SBP = systolic blood pressure; DBP = diastolic blood pressure; Chol = cholesterol; LDL = low-density lipid; HDL = high-density lipid; TG = triglyceride.
Genotype and allele frequencies of ET-1 rs5370 polymorphism.
| Group | Control (%) | Case (%) |
| OR | 95% CI LL | 95% CI UL | |
|---|---|---|---|---|---|---|---|
| Genotype | TT | 17 (8.7) | 115 (65.0) | <0.001 | 62.574 | 30.31 | 129.179 |
| GT | 31 (15.8) | 46 (26.0) | 13.726 | 6.898 | 27.313 | ||
| GG | 148 (75.5) | 16 (9.0) | Ref | ||||
|
| |||||||
| Allele | |||||||
| G | 327 (83.4) | 78 (22) | <0.001 | Ref 17.801 | 12.344 | 25.671 | |
| T | 65 (16.6) | 276 (78) | |||||
| DOM | TT + GT | 48 (24.5) | 161 (91.00) | <0.001 | |||
|
| |||||||
| RES | GG + GT | 179 (91.3) | 62 (35.0) | <0.001 | |||
| Post hoc test | Χ2 |
| |||||
| GG vs. GT | 30.8 | 0.00001 | |||||
| GG vs. TT | 120.65 | 0.00001 | |||||
| GT vs. TT | 31.672 | 0.00001 | |||||
Note: HOM MT = Homozygous mutant; HET = heterozygous; WT = wild type; DOM = dominant; RES = recessive. aChi-square test.
Genotype and allele frequencies of ECE rs212526 polymorphism.
| Group | Control (%) | Case (%) |
| OR | 95% CI LL | 95% CI UL | |
|---|---|---|---|---|---|---|---|
| Genotype | CC | 12 (6.1) | 19 (10.7) | <0.001 | 2.274 | 1.063 | 4.863 |
| CT | 16 (8.2) | 41 (23.2) | 3.679 | 1.971 | 6.868 | ||
| TT | 168 (85.7) | 117 (66.1) | Ref | ||||
|
| |||||||
| Allele | |||||||
| C | 40 (10.2) | 79 (23.3) | <0.001 | 2.528 | 1.675 | 3.816 | |
| T | 352 (89.8) | 275 (77.7) | Ref | ||||
| DOM | CC + CT | 28 (14.3) | 60 (33.9) | <0.001 | |||
|
| |||||||
| RES | TT + CT | 184 (93.9) | 158 (89.3) | <0.001 | |||
| Post hoc test | Χ2 |
| |||||
| CC vs. CT | 0.811 | 0.36 | |||||
| CC vs. TT | 8.6 | 0.0033 | |||||
| CT vs. TT | 10.156 | 0.0014 | |||||
Note: HOM MT = Homozygous mutant; HET = heterozygous; WT = wild type; DOM = dominant; RES = recessive. aChi-square test.
Clinical and biochemical characteristics according to genotypes of ET-1 rs5370 gene polymorphism.
| Parameter | Control (mean ± SD) | Case (mean ± SD) | ||||||
|---|---|---|---|---|---|---|---|---|
| TT | GT | GG |
| TT | GT | GG |
| |
| Age | 36.41 ± 9.36 | 39.06 ± 9.64 | 40.35 ± 8.74 | 0.124 | 55.25 ± 8.37 | 56.33 ± 10 | 57.55 ± 9.5 | 0.565 |
| BMI | 22.71 ± 2.77 | 26.9 ± 5.63 | 25.12 ± 4.22 | <0.001 | 23.81 ± 1.78 | 28.03 ± 4.17 | 29.76 ± 4.62 | <0.001 |
| WHR | 0.92 ± 0.15 | 0.9 ± 0.16 | 0.88 ± 0.06 | 0.583 | 0.83 ± 0.06 | 0.91 ± 0.06 | 0.9 ± 0.11 | 0.016 |
| FPG | 5.39 ± 1.21 | 5.96 ± 1.92 | 5.68 ± 1.65 | 0.117 | 5.33 ± 2.98 | 6.22 ± 1.6 | 6.87 ± 2.56 | 0.041 |
| HBA1C | 2.35 ± 2.78 | 4.91 ± 2.67 | 2.27 ± 3.23 | <0.001 | 6.29 ± 1.57 | 6.02 ± 1.44 | 6.69 ± 2.04 | 0.115 |
| SBP | 119.98 ± 9.64 | 125.16 ± 9.57 | 128.29 ± 12.58 | <0.001 | 153.19 ± 10.02 | 159.15 ± 12.77 | 156.37 ± 12.06 | 0.194 |
| DBP | 77.45 ± 7.42 | 80.19 ± 7.34 | 81.29 ± 6.66 | 0.035 | 93.88 ± 5.43 | 95.8 ± 6.09 | 94.05 ± 5.75 | 0.207 |
| CHOL | 4.88 ± 0.96 | 4.56 ± 0.87 | 4.95 ± 0.83 | <0.001 | 4.65 ± 0.95 | 4.94 ± 1.14 | 5.14 ± 1.1 | 0.188 |
| LDL | 2.62 ± 1 | 2.61 ± 0.73 | 2.88 ± 0.86 | <0.001 | 2.57 ± 0.53 | 2.65 ± 0.92 | 2.99 ± 0.89 | 0.033 |
| HDL | 1.1 ± 0.36 | 1.16 ± 0.32 | 1.02 ± 0.36 | 0.395 | 1.16 ± 0.31 | 1.3 ± 0.46 | 1.24 ± 0.87 | 0.809 |
| TG | 1.51 ± 0.66 | 1.27 ± 0.49 | 1.48 ± 0.82 | 0.173 | 1.97 ± 1.08 | 1.65 ± 0.84 | 1.92 ± 1.04 | 0.279 |
Note: SD = Standard deviation; BMI = body mass index; WHR = waist-to-hip ratio; FPG = fasting plasma glucose; HbA1c = hemoglobin A1c; SBP = systolic blood pressure; DBP = diastolic blood pressure; Chol = cholesterol; LDL = low-density lipid; HDL = High-density lipid; TG = triglyceride. aOne-way ANOVA.
Clinical and biochemical characteristics according to genotypes of ECE rs212526 gene polymorphism.
| Parameter | Control (mean ± SD) | Case (mean ± SD) | ||||||
|---|---|---|---|---|---|---|---|---|
| CC | CT | TT |
| CC | CT | TT |
| |
| Age | 33.58 ± 4.76 | 42.56 ± 11.4 | 36.92 ± 9.3 | 0.028 | 58 ± 4.68 | 57.32 ± 9.39 | 56.76 ± 10.16 | 0.85 |
| BMI | 22 ± 1.36 | 24.74 ± 4.64 | 23.59 ± 3.84 | 0.174 | 31.66 ± 4.41 | 28.75 ± 4.88 | 28.31 ± 4.47 | 0.014 |
| WHR | 0.86 ± 0.08 | 1.03 ± 0.27 | 0.9 ± 0.13 | 0.002 | 0.86 ± 0.23 | 0.91 ± 0.06 | 0.9 ± 0.06 | 0.24 |
| FPG | 5.19 ± 0.91 | 5.75 ± 1.16 | 5.51 ± 1.44 | 0.59 | 7.71 ± 3.4 | 6.65 ± 2.49 | 6.34 ± 2.19 | 0.104 |
| HbA1c | 1.04 ± 2.33 | 3.37 ± 3.11 | 2.79 ± 2.93 | 0.091 | 6.26 ± 3.2 | 6.92 ± 1.94 | 6.37 ± 1.53 | 0.248 |
| SBP | 114.67 ± 10.75 | 121.44 ± 10.6 | 122.02 ± 10.06 | 0.055 | 156.53 ± 9.77 | 157.88 ± 12.09 | 156.48 ± 12.56 | 0.814 |
| DBP | 72.58 ± 5.81 | 77.13 ± 7.24 | 78.73 ± 7.41 | 0.017 | 92.42 ± 5.95 | 95.95 ± 5.7 | 94.33 ± 5.78 | 0.082 |
| Chol | 5.14 ± 1.04 | 4.73 ± 1.32 | 4.82 ± 0.89 | 0.468 | 4.95 ± 1.02 | 5.11 ± 1.25 | 5.04 ± 1.07 | 0.871 |
| LDL | 3.15 ± 0.88 | 2.34 ± 0.91 | 2.63 ± 0.95 | 0.074 | 2.76 ± 0.83 | 2.75 ± 0.98 | 2.92 ± 0.86 | 0.492 |
| HDL | 1.16 ± 0.29 | 1.04 ± 0.41 | 1.1 ± 0.35 | 0.664 | 1.28 ± 0.4 | 1.19 ± 0.35 | 1.27 ± 0.88 | 0.854 |
| TG | 1.64 ± 0.53 | 1.4 ± 0.44 | 1.46 ± 0.68 | 0.621 | 1.68 ± 0.88 | 1.92 ± 1.22 | 1.86 ± 0.93 | 0.679 |
Note: SD = standard deviation; BMI = body mass index; WHR = waist-to-hip ratio; FPG = fasting plasma glucose; HbA1c = hemoglobin A1c; SBP = systolic blood pressure; DBP = Diastolic blood pressure; Chol = cholesterol; LDL = low-density lipid; HDL = high-density lipid; TG = triglyceride. aOne-way ANOVA.
Genotypic distribution in female and male.
| Gene | Gender | Genotype | Control | Case |
| OR | 95% CI LL | 95% CI UL |
|---|---|---|---|---|---|---|---|---|
| ET-1 | Male | GG | 77 (78.6) | 9 (8.5) | <0.001 | Ref | ||
| GT | 14 (14.3) | 31 (29.2) | <0.001 | 23.178 | 5.618 | 95.629 | ||
| TT | 7 (7.1) | 66 (62.3) | <0.001 | 71.696 | 14.69 | 349.912 | ||
| Female | GG | 71 (72.4) | 7 (9.9) | <0.001 | Ref | |||
| GT | 17 (17.3) | 15 (21.1) | 0.185 | 2.764 | 0.614 | 12.433 | ||
| TT | 10 (10.2) | 49 (69) | <0.001 | 13.683 | 3.339 | 56.061 | ||
|
| ||||||||
| ECE | Male | CC | 5 (5.1) | 8 (7.5) | 0.736 | 0.83 | 0.078 | 8.847 |
| CT | 9 (9.2) | 24 (22.6) | 0.837 | 1.306 | 0.103 | 16.574 | ||
| TT | 84 (85.7) | 74 (69.8) | 0.877 | Ref | ||||
| Female | CC | 7 (7.1) | 11 (15.5) | 0.34 | 0.348 | 0.05 | 2.404 | |
| CT | 7 (7.1) | 17 (23.9) | 0.799 | 0.751 | 0.083 | 6.809 | ||
| TT | 84 (85.7) | 43 (60.6) | 0.284 | Ref | ||||
Notes: CI = confidence interval; the analysis was adjusted based on age and BMI as covariates.